# OnCo record met-ex14 (biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/biomarkers/met-ex14/>
  a schema:MedicalTest ;
  onco:kind "biomarker" ;
  schema:identifier "met-ex14" ;
  schema:name "MET exon 14 skipping mutation"@en ;
  schema:alternateName "METex14"@en, "MET exon 14 skipping"@en, "MET ex14"@en, "METΔex14"@en, "MET exon 14 alteration"@en, "MET splice site mutation"@en ;
  schema:description "MET exon 14 skipping is a splice-site change that lets the MET receptor escape degradation and keep signalling. It is found in 3 to 4 percent of lung cancers and is treated with capmatinib or tepotinib."@en ;
  schema:url <https://onco.cc/biomarkers/met-ex14/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=455892c3-d144-4ba8-9ab4-79cabff9876d>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80a0f1b9-071a-47f5-9e67-32d638a669dc> ;
  onco:tag "biomarker", "met" ;
  onco:related <https://onco.cc/biomarkers/met-amplification-readout/>, <https://onco.cc/biomarkers/met-overexpression/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:drugs <https://onco.cc/drugs/capmatinib/>, <https://onco.cc/drugs/tepotinib/>, <https://onco.cc/drugs/capmatinib-tepotinib/>, <https://onco.cc/drugs/foundationone-cdx/> ;
  onco:terms <https://onco.cc/terms/met-exon-14-skipping/>, <https://onco.cc/terms/ngs/> .